Fierce Pharma Biopharma News & Insights
5 天之前 · Fierce Pharma delivers breaking news and analysis about drug companies, the FDA and the broader pharma industry, including manufacturing, marketing and finance.
Fierce Pharma Asia—AstraZeneca-CSPC heart med deal; Astellas' …
3 天之前 · AstraZeneca has bagged a cardiovascular disease candidate from China's CSPC Pharma in a deal potentially worth $2 billion. Astellas is shuffling its cell therapy research team and investing in a ...
Asia - Fierce Pharma
2024年10月4日 · In China, Lilly plans $200M expansion to make tirzepatide meds. Eli Lilly will expand its manufacturing site in Suzhou China, investing $200 million to produce in-demand drugs Mounjaro and ...
A revival in neuro therapeutics | Fierce Pharma
3 天之前 · A revival in neuro therapeutics. The neuroscience sector has seen a surge in investment over the past year, leading to breakthroughs and high-stakes deals, especially in the closing months of 2023 ...
Dupixent takes pharma DTC top spot in September
2024年10月7日 · Skyrizi has been dominating the 2024 DTC ranking list alongside Rinvoq, which came in third in September, though spending on the med’s commercials dropped by a significant $6.2 million. Dupixent ...
Pharma | Fierce Pharma
2024年10月7日 · The FDA has approved Pfizer's Hympavzi, an anti-tissue factor pathway inhibitor for patients age 12 and older with hemophilia A or B. Kevin Dunleavy Oct 11, 2024 4:20pm. Connect. The Team. Advertise.
Fierce 50 of 2024 | Fierce Pharma
I’m honored to introduce the second edition of the Fierce 50, where we once again spotlight the innovators and leaders driving the future of healthcare, pharma and biotech. This year’s ...
Biotech - Fierce Pharma
2024年9月26日 · Pfizer targets broad Talzenna label in prostate cancer. Pfizer hopes an overall survival showing could expand Talzenna's reach in mCRPC beyond those with HRR mutations. Angus Liu Oct 10, 2024 10 ...
2021 drug approvals: In a year dominated by COVID, biopharma …
Each year, many scientists and other experts working in the biopharma industry see years of their work culminate in FDA approvals. With the COVID-19 crisis stretching into its third year, the 2021 ...
AstraZeneca plans independent drug supply chains for US and …
2024年3月27日 · As geopolitical tensions threaten to disrupt pharmaceutical supply chains, AstraZeneca is making plans to manufacture drugs for the U.S. and China markets independently from one another. “We ...